Trial Profile
A phase 3, parallel group, randomized, double-blind, double-dummy, placebo and active-controlled multicenter trial to investigate the efficacy, tolerability and safety of fesoterodine sustained release in subjects with overactive bladder syndrome
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Sep 2021
Price :
$35
*
At a glance
- Drugs Fesoterodine (Primary) ; Tolterodine
- Indications Overactive bladder
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer; UCB
- 01 Aug 2012 New source identified and integrated (German Clinical Trials Register, DRKS00004018).
- 01 Aug 2012 New source identified and integrated (German Clinical Trials Register, DRKS00004018).
- 09 Apr 2008 Pfizer has replaced UCB Pharma as a trial sponsor, according to ClinicalTrials.gov.